INCYTE CORP

Specialised Therapeutics partners with Incyte to launch Opzelura in Australia, offering a new JAK‑inhibitor cream for chronic skin conditions and expanding dermatology treatment options.

IncYTE files Form 4 & 144: see how President Pablo Cagnoni’s recent share sales reflect routine insider‑trading compliance and impact investor confidence.

Incite Corp boosts its cell‑therapy pipeline with a long‑term partnership that secures advanced equipment, scales production, and accelerates clinical readiness.

Incyte’s Q2 2026 earnings boost revenue & earnings, driving stock to a 52‑week high thanks to Jakafi growth, Opzelura CMS gains and a strong pipeline outlook.

Incyte’s latest executive option exercises reveal a strategic focus on TSR‑linked incentives and retention, hinting at confidence in growth while spotlighting dilution risks and competitive dynamics.

Incyte’s Latarcibart, a once‑monthly subcutaneous antibody, cut bleeding rates by 76% in all VWD subtypes, offering a safer, needle‑free alternative to IV factor replacement.

Explore how changing reimbursement models and operational challenges are reshaping pharma equity and the viability of high‑cost therapies like CAR‑T and gene editing.

IncYTE Corp. sees mixed week: first‑half rally driven by new product pipeline and partnership wins, followed by a pullback amid market volatility; investors weigh steady valuation, incremental revenue growth, and R&D focus against pricing pressures …

Incyte’s EMA approval of Opzelura, a steroid‑free topical JAK inhibitor, offers a safe, effective alternative for moderate atopic dermatitis and could reshape Europe’s dermatology market.

Incyte’s EMA approval of Opzelura offers a steroid‑free, JAK‑inhibitor cream that swiftly relieves itch in moderate atopic dermatitis, boosting Incyte’s dermatology revenue and patient outcomes.